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Objectives. Autoimmune diseases (AD) may be associated with coeliac disease (CD), but specific risk factors have been poorly
investigated. The aim of this study was to assess the spectrum of AD and its specific risk factors associated in a series of adult
coeliac patients. Materials and Methods. We performed a single-center case-control study including adult newly diagnosed CD
patients. To evaluate the risk factors of the association between AD and CD, 341 coeliac patients included were categorized on
the basis of AD presence: 91 cases with at least one AD and 250 controls without AD were compared for clinical, serological,
and histological features. Eighty-seven cases were age-gender-matched with 87 controls. Results. Among 341 CD patients,
26.6% of CD patients had at least one AD. Endocrine and dermatological diseases were the most prevalent AD
encountered: autoimmune thyroiditis was present in 48.4% of cases, psoriasis in 17.6%, and type I diabetes and dermatitis
herpetiformis in 11%, respectively. At logistic regression, factors associated with AD were a positive 1st-degree family history of
AD (OR 3.7, 95% CI 1.93–7), a body mass index≥ 25 kg/m2 at CD diagnosis (OR 2.95%, CI 1.1–3.8), and long standing
presentation signs/symptoms before CD diagnosis (>10 years) (OR 2.1, 95% CI 1.1–3.7). Analysis on age-gender-matched
patients confirmed these results. Conclusions. CD patients with family history of AD, overweight at CD diagnosis, and a delay of
CD diagnosis had an increased risk of having another AD. The benefit of CD screening in these specific subsets of patients with
AD awaits further investigation.
1. Introduction
Coeliac disease (CD) is an immune-mediated enteropathy
triggered by the ingestion of gluten-containing grains in
genetically susceptible persons. CD is one of the most
common causes of chronic malabsorption and affects
approximately 1% of the Western population [1, 2]. In CD
patients, a significantly increased prevalence of autoimmune
disorders (AD), including systemic diseases and organ-
specific diseases, has been reported compared to healthy
controls, with an estimated prevalence ranging from 15 to
30% [3, 4]. Conversely, a significantly increased prevalence
of CD has been documented in individuals with several
AD. Screening for CD is recommended in patients affected
by type I diabetes mellitus and autoimmune thyroid disease
[5]. The association among CD and AD has been suggested
to be due to shared genetic features between CD and other
immune-mediated conditions, similar environmental trig-
gers, and the loss of intestinal barrier [6, 7]. Previous studies
have examined factors associated with the coexistence of AD
among CD patients providing conflicting results [8–10]. The
aim of the present study was to assess the spectrum of AD
and its specific risk factors associated in a series of adult
CD patients.
2. Materials and Methods
2.1. Study Population and Design. This was a single-center
case-control study reported according to the checklist
items indicated in the STROBE guidelines [11]. Records of
patients who consecutively underwent oesophago-gastro-
duodenoscopy with duodenal biopsies and had histological
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features compatible with CD at the referral Coeliac Disease
Center of Sant’Andrea University Hospital, Rome, from
2001 to 2017 were assessed for eligibility. The study was
database driven, and data from 341 CD patients (median
age 35, range 18–76 years, females, 77.4%) with the following
inclusion criteria were considered: CD diagnosis in adult-
hood (>18 years at time of gastroscopy) with duodenal
villous atrophy (Marsh 3 A-C) with complete clinical and
biochemical data recorded at the first visit. Patients with
incomplete serological or histological data for CD diagnosis,
partial clinical and personal data, and patients with histolog-
ical reports compatible with nonatrophic CD (Marsh 1-2)
were excluded (Figure 1). At the time of CD diagnosis, a
structured questionnaire comprising personal and clinical
data including associated AD was filled in for each patient.
Table 1 showed baseline characteristics of included patients.
The diagnosis of AD (autoimmune thyroiditis, type 1 diabe-
tes mellitus, dermatological diseases such as dermatitis
herpetiformis, psoriasis, alopecia, and vitiligo, autoimmune
liver diseases, pernicious anemia, systemic lupus erythemato-
sus, rheumatoid arthritis, inflammatory bowel diseases,
multiple sclerosis, and others) was based on the evaluation
of the clinical history and the revision of clinical charts
and/or reports from previous specialist examinations. To
evaluate the risk factors of the association between AD and
CD, all included patients were categorized on the basis of
the presence or absence of AD.
As shown in the flowchart (Figure 1), of the 341 CD
patients included, 91 patients (cases) with at least one
AD (26.6%) and 250 CD patients without AD (controls)
were evaluated.
The diagnosis of CD was based on small intestinal
biopsies (n = 5) taken from the bulb and the second part
of the duodenum and CD specific serological assays.
Duodenal histological damage was classified according to
Oberhuber et al. and Marsh [12, 13], and only patients with
duodenal villous atrophy (Marsh 3 A-C) were included.
According to Oslo classification, CD presentation was
classified as (1) classical CD with malabsorption syndrome
(diarrhea, weight loss); (2) nonclassical CD with gastroin-
testinal symptoms (except for diarrhea) and extraintestinal
manifestations; and (3) subclinical CD with signs and
symptoms below the threshold of detection [14]. At the
first visit, serological and histological data were recorded,
weight and height for the calculation of body mass index
(BMI) were determined in each patient and classified;
according to WHO, normal weight if BMI was >18.5 kg/m2
to ≤24.9 kg/m2, underweight if was BMI< 18.5 kg/m2, while
overweight if BMI was ≥25 kg/m2.
In addition, all patients underwent serological stud-
ies including CD specific serological assays with anti-
transglutaminase antibodies (tTG-IgA), anti-endomysial
antibodies (EMA-IgA) together with anti-transglutaminase
antibodies (Ttg-IgG) in case of IgA deficiency. Genetic test-
ing was obtained in selective cases of incongruity between
histological and serological features. All patients were tested
Biopsy reports compatible with
diagnosis of CD (from 2001 to 2017):
588
Exclusion criteria:
(i) Unable to retrieve AD data
(ii) Partial data of CD diagnosis
(iii) Marsh 1-2
Included patients:
341
91 CD + AD
Inclusion criteria:
(i) Age ≥ 18 years
(ii) Duodenal villous atrophy (Marsh 3 A-C)
250 CD without AD 
Excluded: 247
Cases Controls
Figure 1: Flowchart selection of study population. Finally, 341 coeliac patients meeting the inclusion criteria were categorized into
two groups: 91 cases (coeliac patients with autoimmune diseases) and 250 controls (coeliac patients without autoimmune diseases).
CD: coeliac disease; AD: autoimmune disease.
Table 1: Baseline characteristics of 341 included coeliac patients.
Female gender 77.4
Age at coeliac disease diagnosis, years,
median (range)
35 (18–76)
Body mass index, kg/m2, median (range) 21.3 (14.5–38.2)
Gastrointestinal symptoms leading to coeliac
disease diagnosis
70.7
(i) Classical presentation 33.7
(ii) Nonclassical presentation 55.7
(iii) Subclinical presentation 12
Marsh 3C 52.8
Family history of coeliac disease 16.3
Family history of autoimmune disease 18.7
Data are expressed as percentage where not otherwise indicated.
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for the following laboratory indices: haemoglobin, albumin,
cholesterol, triglycerides, and ferritin (anemia was defined
as haemoglobin< 12 g/100ml in women and <13.5 g/100ml
in men). Thyroid hormones (triiodothyronine, free thyroxin,
and basal thyrotropin) and antiperoxidase antibodies were
routinely assessed in each patient at CD diagnosis time, and
the diagnosis of autoimmune thyroiditis was made as
previously reported [15, 16].
2.1.1. Statistical Analyses. For the computation of sampling,
data from the previously published papers of AD prevalence
in coeliac patients were used [4, 17]. Assuming a normal
distribution, we calculated that 343 patients would have been
required to yield a statistical power of 95% and a probability
of type I error of 0.05 and type II error of 0.01. Data were
expressed as medians, ranges, and percentages. Comparisons
between cases and controls were made using Fisher’s exact
test, chi-square test, and Mann–Whitney U test, as appropri-
ate. At univariate analysis, the two groups were compared for
clinical features including gender, age at CD diagnosis, BMI,
signs and symptoms leading to CD diagnosis and their
duration before CD diagnosis (more than 10 years), 1st-
degree family history for CD or AD, and presence of severe
duodenal atrophy (March 3C) as well as serological features
including haemoglobin, albumin, cholesterol, triglycerides,
and ferritin. Odds ratios (ORs) and 95% confidence intervals
(CIs) were used to describe the associations and were
obtained by logistic regression analysis performed on the
whole group of patients. Two-tailed p values< 0.05 were
considered statistically significant. According to the STROBE
guidelines, to increase the study’s efficiency by ensuring
similarity in the distribution of variables between cases and
controls [11], we repeated a logistic regression analyses by
using the above cited covariants on controls individually
matched to cases by gender and age (years ±1) at CD diagno-
sis. For 87 cases, one control was identified who met all
matching criteria (1 : 1). When more than one control was
available, we used a random selection method considering
the lower number of the histology report. Four cases were
excluded because they did not have adjusted controls meet-
ing matching criteria. Statistical analyses were performed
using a dedicated Software (MedCalc software, Mariakerke,
Belgium, version 12.7.8).
3. Results
3.1. AD Associated with CD.Overall, in 26.6% of included CD
patients at least one AD was associated. The most prevalent
AD were endocrine and dermatological AD. As shown in
detail in Table 2, autoimmune thyroiditis was present in
48.4% of cases, while psoriasis in 17.6% and type I diabetes
and dermatitis herpetiformis in 11%, respectively. Only one
AD was present in 81.3% (n = 74), and more than one AD
in 18.7% (n = 17) of cases; when more than one AD was
associated, autoimmune thyroiditis was the most frequent
(64.7%). In 82 (90%) of the cases, the diagnosis of AD was
already known at the CD diagnosis time, whereas in nine
patients, the diagnosis of AD was performed concomitantly
as part of the diagnostic work-up for CD (within 3 months
from CD diagnosis).
3.2. Risk Factors for the Concomitant Presence of AD in CD
Patients. Comparing cases and controls, CD patients with
AD presented more frequently with overweight at CD
diagnosis time (29.8% versus 17.2%; p = 0 019), with signs/
symptoms leading to CD diagnosis persisting for more than
10 years before CD diagnosis (39% versus 26.3%; p = 0 03)
and with a positive 1st-degree family history for AD (33.7%
versus 13.2%; p < 0 0001). No differences were found among
cases and controls with regard to gender, median age at
CD diagnosis, 1st-degree family history of CD, severity
of duodenal histological damage (Marsh 3C), and presence
of gastrointestinal symptoms at CD diagnosis.
Moreover, among cases and controls, the proportions of
nonclassical, classical, and subclinical subtypes according to
the Oslo classification were similar with the following per-
centages for cases and controls, respectively: nonclassical
CD (61.5% versus 53.6%; p = 0 21); classical CD (28.6%
versus 35.6%; p = 0 24), and subclinical CD (12% versus
12%; p = 1). Concerning nutritional parameters, univariate
analysis showed that between the two groups, there were no
Table 2: Spectrum of autoimmune diseases observed in 91 adult
patients with coeliac disease.
Number and
percentages (%) of
AD in 91 cases
Percentages of
AD in all included
CD patients
Endocrine diseases 54 (59.3) 15.8
Autoimmune thyroid
diseases
44 (48.4) 12.9
Type I diabetes mellitus 10 (11) 2.9
Dermatological diseases 40 (44) 11.7
Psoriasis 17 (18.7) 4.9
Dermatitis herpetiformis 10 (11) 2.9
Alopecia areata 7 (7.7) 2
Vitiligo 4 (4.4) 1.2
Lichen sclerosus 2 (2.2) 0.6
GI diseases 3 (3.3) 0.9
Autoimmune hepatitis 1 (1.1) 0.3
Inflammatory bowel
diseases
1 (1.1) 0.3
Pernicious anemia 1 (1.1) 0.3
Rheumatological/
connective tissue diseases
4 (4.4) 1.2
Rheumatoid arthritis 1 (1.1) 0.3
Spondyloarthritis 1 (1.1) 0.3
Systemic lupus
erythematosus
1 (1.1) 0.3
Connettivitis 1 (1.1) 0.3
Others 2 (2.2) 0.6
Sarcoidosis 1 (1.1) 0.3
Multiple sclerosis 1 (1.1) 0.3
AD: autoimmune disease; CD: coeliac disease.
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significant differences of albumin, cholesterol, triglyceride,
ferritin, and haemoglobin values.
At logistic regression model, factors linked to the asso-
ciation of AD and CD were a positive 1st-degree family
history of AD (OR 3.7, 95% CI 1.93 to 7), a body mass
index≥ 25 kg/m2 (OR 2, 95% CI 1.1 to 3.8), and long
standing presentation signs/symptoms before CD diagnosis
(>10 years) (OR 2.1, 95% CI 1.1 to 3.7), while other features
as gender, age≥ 40 years, clinical presentation, or presence of
severe duodenal atrophy (March 3C) were not associated.
The logistic regression model performed on age-gender-
matched cases and controls confirmed the same risk factors
found above (Table 3).
4. Discussion
In this case-control study, nearly one-third of our series of
adult coeliac patients (26.6%) had at least one cooccurring
AD, confirming the previously reported data [10]. A genetic
overlap between CD and other immune-mediated conditions
could be a plausible explanation for this increased prevalence
in coeliac patients compared to healthy controls [6, 7].
Genome-wide association studies (GWAS) have, indeed,
suggested common genetic bases located in coding and
noncoding DNA regions for CD and other AD such as
type I diabetes, ulcerative colitis, rheumatoid arthritis,
and Crohn’s disease [18, 19]. Endocrine and dermatological
AD were the most common associated AD in our series,
occurring in 15.8% and 11.7%, respectively, of all included
patients. More specifically, autoimmune thyroiditis (12.8%),
psoriasis (4.6%), and type I diabetes (2.9%) were the most
frequent AD keeping in step with the previously reported
data [3, 20]. The prevalence of dermatitis herpetiformis was
instead lower (2.9%) than that observed in most previous
studies (5–10%); this may possibly be explained by the
decreasing occurrence of dermatitis herpetiformis as found
by an Italian larger series (4%) [21] and in a recent Dutch
study (3.2%) [4].
We found the following risk factors linked to the
cooccurrence of AD in coeliac patients: family history of
autoimmunity, overweight at CD diagnosis, and a delayed
diagnosis of CD with a long interval between the first signs/
symptoms leading to CD diagnosis and CD diagnosis. With
regard to family history of AD, we found a presence of
autoimmune diseases of 33.7% among first-degree family
members of cases and 13.2% of first-degree family members
of controls, percentages that in both cases resulted higher
than the general population prevalence all over the world
(3–5%). A previous paper showed a 2.4-fold risk (CI 95%
1.71–3.31) to develop AD in pediatric and adult CD patients
with positive family history [8]. Indeed, among several risk
factors associated with the onset of AD, family history of
AD, also known as familial autoimmunity, has been docu-
mented showing how AD cluster in families [22]. In fact,
one study [23] observed a significantly increased risk of
noncoeliac AD in first-degree relatives of coeliac patient
explaining this phenomenon by genetic factors but also by
ascertainment bias and environmental factors.
In our series, coeliac patients with an associated AD
presented more frequent overweight at CD diagnosis time
(31%) than patients with CD alone (17.2%). To the best of
our knowledge, only one cross-sectional study previously
investigated the relation between BMI and autoimmune
disorders in CD, in particular with immune-mediated skin
diseases, demonstrating that overweight was positively
related to the prevalence of dermatitis herpetiformis and
psoriasis in adults with untreated CD [24]. Taking into
consideration only the overweight cases of the present study,
we found that autoimmune thyroiditis was the most preva-
lent AD in accordance with the above results (16/28) and
only three and four patients presented with psoriasis and
dermatitis herpetiformis, respectively. Eventual confounding
factors possibly explaining overweight were found in five of
28 overweight cases: two patients had a diagnosis of type I
diabetes in childhood and were insulin dependent and three
patients had a diagnosis of autoimmune thyroiditis during
CD diagnosis work-up and they still were not on levothyrox-
ine treatment at the first CD visit time, perhaps explaining
Table 3: Risk factors for the association of autoimmune diseases
(AD) in coeliac disease (CD) patients by logistic regression
analysis in the whole group of included patients and in gender-
age-matched patients.
All included
patients (n = 341)
OR (95% CI)
Gender-age matched
patients (n = 172)
OR (95% CI)
Age at CD diagnosis
<40 1.0 —
≥40 1.2 (0.7–2.1)
Gender
Male 1.0 —
Female 0.65 (0.3–1.3)
Overweight
(BMI≥ 25 kg/m2)
No 1.0
Yes 2 (1.1–3.8) 8.4 (2.9–24.8)
Gastrointestinal
symptoms leading to
CD diagnosis
No 1.0
Yes 1.2 (0.6–2.3) 0.6 (0.2–1.6)
Severe histological
damage (Marsh 3C)
No 1.0
Yes 0.95 (0.6–1.7) 0.96 (0.4–2.15)
Family history of AD
No 1.0
Yes 3.7 (1.9–7) 6.9 (2.2–21.7)
Duration of
symptoms≥ 10 years
before CD diagnosis
No 1.0
Yes 2.1 (1.1–3.7) 19.6 (5.3–73.1)
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their weight increase due to an initial hypothyroidism. In
addition, nutritional parameters were similar between over-
weight and normal weight patients. We are not able to
explain this association but we can speculate that the proin-
flammatory condition present in overweight may favor the
development of several diseases, including also AD, due to
the key role of white adipose tissue as an active endocrine
organ, playing a role in immune and inflammatory processes
by releasing proinflammatory mediators in common with
immune-mediated diseases [25].
Another observed risk factor was the delay of CD
diagnosis after onset of signs/symptoms among cases. In
literature, there are conflicting reports on the relation
between a longer exposure to gluten in patients with
higher age at CD diagnosis and the increased risk to
develop AD. Previous Italian [9] and French [8] studies
showed a role of these two factors, not confirmed by
other two studies from Italy [10] and Finland [26].
In our study, no difference was found among cases and
controls with regard to median age at CD diagnosis even if
CD patients with associated AD had a delayed diagnosis of
CD with a long interval between the first signs/symptoms
leading to CD diagnosis and CD diagnosis.
Albeit, it is not clear whether coexistence of AD in coeliac
patients could be considered a comorbidity with their own
specific de novo dysreactivity of the immune system rather
than CD-dependent diseases as a consequence of inflamma-
tion of the gut induced by gluten. Taking together these data,
the duration of untreated disease might be the real risk factor
rather than the age of patients at the time of CD diagnosis. In
turn, this might be due to a decreasing number of patients
with classical CD (diarrhea, weight loss) [21] as also sup-
ported by our study, in which the nonclassical CD was the
most frequent presentation form. This changing clinical pro-
file and the underestimation of nonclassical gastrointestinal
symptoms, often attributed to the already known AD, might
be one possible explanation for a delayed diagnosis of CD.
We are aware of some limitations of this study. First,
although coeliac patients were included prospectively, this
study was mainly database driven and data were analyzed
retrospectively. The aim of our study was to analyze factors
associated with an increased risk of AD among adult coeliac
patients; however, in this case-control study, the lack of a
healthy control group did not allow to evaluate the relative
risk of this association.
5. Conclusion
In summary, the present study confirms the wide spectrum
of different AD among CD patients and shows that the risk
factors for associated AD were positive family history of
AD, overweight at CD diagnosis time, and a delay of CD
diagnosis. The benefit of CD screening in these specific
subsets of patients with AD awaits investigation.
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